- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00797745
A Pharmacokinetics/Pharmacodynamics Study of SCH 900518 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C (Protocol No. P05104AM2)(COMPLETED) (NEXT-1)
21. Januar 2015 aktualisiert von: Merck Sharp & Dohme LLC
A Study of SCH 900518 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C (Protocol No. P05104)
SCH 900518 is a potent oral inhibitor of HCV NS3 protease which disrupts hepatitis C virus (HCV) polyprotein processing.
SCH 900518, when added to the current standard of care (SOC), peginterferon-alfa plus ribavirin, would likely increase the proportion of patients achieving undetectable HCV-RNA levels and sustained virologic response (SVR).
In this study, SCH 900518 would be used in combination with low doses of ritonavir to enhance the levels of SCH 900518 within the body and reduce the number of daily SCH 900518 tablets required.
The purpose of this study is to identify the optimal dose and schedule (once or twice a day) of SCH 900518 plus ritonavir in previously untreated patients with genotype 1 chronic hepatitis C when given in combination with SOC.
The study compares SOC to 6 experimental arms.
In the experimental arms, SOC plus SCH 900518 doses of 200, 400 and 600 mg once daily or 100 mg twice daily with ritonavir 100 mg once or twice daily will be explored.
The benefits of a 4 week lead-in with PegIntron and ribavirin prior to the addition of SCH 900518 will also be explored.
Studienübersicht
Status
Abgeschlossen
Bedingungen
Intervention / Behandlung
Studientyp
Interventionell
Einschreibung (Tatsächlich)
111
Phase
- Phase 2
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
18 Jahre bis 55 Jahre (Erwachsene)
Akzeptiert gesunde Freiwillige
Nein
Studienberechtigte Geschlechter
Alle
Beschreibung
Inclusion Criteria:
- Adult subjects with CHC HCV genotype 1 with no previous treatment for CHC
- 18 to 55 years of age
- Weight between 40 and 125 kg
- Previously documented CHC genotype 1 infection
- Liver biopsy within 2 years of Screening with histology consistent with chronic hepatitis C and no evidence of bridging fibrosis or cirrhosis
- Subject and subject's partner(s) must each agree to use acceptable methods of contraception for at least 2 weeks prior to Day 1 and continue until at least 6 months after last dose of study drug
- Subjects must be willing to give written informed consent
Exclusion Criteria:
- Prior treatment for hepatitis C other than herbal remedies
- HIV positive or known to be co-infected with hepatitis B
- Medically significant gallbladder or hepatobiliary findings on Screening ultrasound
- Use of any known significant inducers or substrates of CYP3A4 two weeks prior to start of study medications
- Use of herbal supplements (Milk Thistle permitted)
- Diabetic and hypertensive subjects with clinically significant ocular examination findings
- Current moderate or severe depression
History of depression associated with any of the following:
- Hospitalization for depression
- Electroconvulsive therapy for depression.
- Depression that resulted in a prolonged absence from work and/or significant disruption of daily functions
- Suicidal or homicidal ideation and/or attempt
- History of severe psychiatric disorders
- Past history or current use of lithium
- Clinical diagnosis of substance abuse of alcohol, intravenous drugs, inhalational (not including marijuana), psychotropics, narcotics, cocaine use, prescription or over-the-counter drugs within 5 years of Day 1
- Past or current use of opiate agonist substitution therapy
- Any known pre-existing medical condition (CNS, cardiac, pulmonary, immune mediated) that could interfere with the subject's participation in and completion of the study
- Active clinical gout within the last year
- Hemoglobinopathy or coagulopathy
- Myelodysplastic syndromes
- Organ transplants other than cornea and hair
- Poor venous access that precludes routine peripheral blood sampling or an indwelling venous catheter
- Subjects with a history of gastric surgery (eg, stapling, banding, bypass) or subjects with a history of malabsorption disorders (eg, celiac sprue disease)
- Evidence of active or suspected malignancy, or a history of malignancy, within the last 5 years (except adequately treated basal cell carcinoma of the skin). Subjects under evaluation for malignancy are not eligible.
- Subjects who are pregnant or nursing
- Subjects who intend to become pregnant during the study period
- Male subjects with partners who are, or intend to become, pregnant during the study period
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Aktiver Komparator: Standard of Care
PegIntron 1.5 mcg/kg SC weekly plus ribavirin 600 to 1400 mg daily (weight-based) by mouth twice daily for 48 weeks.
|
1.5 mcg/kg subcutaneously weekly for up to 24 or 48 weeks
Andere Namen:
ribavirin 600 to 1400 mg daily (weight-based dosing) by mouth twice daily for up to 24 or 48 weeks
Andere Namen:
SCH 900518 100 mg tablets taken as 200 mg PO QD, 100 mg PO BID, 400 mg PO QD, or 600 mg PO QD for 12 weeks.
Ritonavir 100 mg capsules taken as 100 mg PO QD or 100 mg PO BID for 12 weeks.
Andere Namen:
|
Experimental: 2
PegIntron 1.5 mcg/kg SC weekly plus ribavirin 600 to 1400 mg daily (weight-based) by mouth twice daily plus SCH 900518 200 mg daily plus ritonavir 100 mg daily for 12 weeks.
Depending on HCV-RNA levels after 4 weeks of SCH 900518, patients will receive an additional 12 or 36 weeks of PegIntron/ribavirin.
Total treatment duration will be 24 or 48 weeks.
|
1.5 mcg/kg subcutaneously weekly for up to 24 or 48 weeks
Andere Namen:
ribavirin 600 to 1400 mg daily (weight-based dosing) by mouth twice daily for up to 24 or 48 weeks
Andere Namen:
SCH 900518 100 mg tablets taken as 200 mg PO QD, 100 mg PO BID, 400 mg PO QD, or 600 mg PO QD for 12 weeks.
Ritonavir 100 mg capsules taken as 100 mg PO QD or 100 mg PO BID for 12 weeks.
Andere Namen:
|
Experimental: 3
PegIntron 1.5 mcg/kg SC weekly plus ribavirin 600 to 1400 mg daily (weight-based) by mouth twice daily plus SCH 900518 400 mg daily plus ritonavir 100 mg daily for 12 weeks.
Depending on HCV-RNA levels after 4 weeks of SCH 900518, patients will receive an additional 12 or 36 weeks of PegIntron/ribavirin.
Total treatment duration will be 24 or 48 weeks.
|
1.5 mcg/kg subcutaneously weekly for up to 24 or 48 weeks
Andere Namen:
ribavirin 600 to 1400 mg daily (weight-based dosing) by mouth twice daily for up to 24 or 48 weeks
Andere Namen:
SCH 900518 100 mg tablets taken as 200 mg PO QD, 100 mg PO BID, 400 mg PO QD, or 600 mg PO QD for 12 weeks.
Ritonavir 100 mg capsules taken as 100 mg PO QD or 100 mg PO BID for 12 weeks.
Andere Namen:
|
Experimental: 4
4 week lead-in with PegIntron 1.5 mcg/kg SC weekly plus ribavirin 600 to 1400 mg daily (weight-based) by mouth twice daily followed by PegIntron plus ribavirin plus SCH 900518 200 mg daily plus ritonavir 100 mg daily for 12 weeks.
Depending on HCV-RNA levels after 4 weeks of SCH 900518, patients will receive an additional 8 or 32 weeks of PegIntron/ribavirin.
Total treatment duration will be 24 or 48 weeks.
|
1.5 mcg/kg subcutaneously weekly for up to 24 or 48 weeks
Andere Namen:
ribavirin 600 to 1400 mg daily (weight-based dosing) by mouth twice daily for up to 24 or 48 weeks
Andere Namen:
SCH 900518 100 mg tablets taken as 200 mg PO QD, 100 mg PO BID, 400 mg PO QD, or 600 mg PO QD for 12 weeks.
Ritonavir 100 mg capsules taken as 100 mg PO QD or 100 mg PO BID for 12 weeks.
Andere Namen:
|
Experimental: 5
4 week lead-in with PegIntron 1.5 mcg/kg SC weekly plus ribavirin 600 to 1400 mg daily (weight-based) by mouth twice daily followed by PegIntron plus ribavirin plus SCH 900518 400 mg daily plus ritonavir 100 mg daily for 12 weeks.
Depending on HCV-RNA levels after 4 weeks of SCH 900518, patients will receive an additional 8 or 32 weeks of PegIntron/ribavirin.
Total treatment duration will be 24 or 48 weeks.
|
1.5 mcg/kg subcutaneously weekly for up to 24 or 48 weeks
Andere Namen:
ribavirin 600 to 1400 mg daily (weight-based dosing) by mouth twice daily for up to 24 or 48 weeks
Andere Namen:
SCH 900518 100 mg tablets taken as 200 mg PO QD, 100 mg PO BID, 400 mg PO QD, or 600 mg PO QD for 12 weeks.
Ritonavir 100 mg capsules taken as 100 mg PO QD or 100 mg PO BID for 12 weeks.
Andere Namen:
|
Experimental: 6
PegIntron 1.5 mcg/kg SC weekly plus ribavirin 600 to 1400 mg daily (weight-based) by mouth twice daily plus SCH 900518 100 mg twice daily plus ritonavir 100 mg twice daily for 12 weeks.
Depending on HCV-RNA levels after 4 weeks of SCH 900518, patients will receive an additional 12 or 36 weeks of PegIntron/ribavirin.
Total treatment duration will be 24 or 48 weeks.
|
1.5 mcg/kg subcutaneously weekly for up to 24 or 48 weeks
Andere Namen:
ribavirin 600 to 1400 mg daily (weight-based dosing) by mouth twice daily for up to 24 or 48 weeks
Andere Namen:
SCH 900518 100 mg tablets taken as 200 mg PO QD, 100 mg PO BID, 400 mg PO QD, or 600 mg PO QD for 12 weeks.
Ritonavir 100 mg capsules taken as 100 mg PO QD or 100 mg PO BID for 12 weeks.
Andere Namen:
|
Experimental: 7
4 week lead-in with PegIntron 1.5 mcg/kg SC weekly plus ribavirin 600 to 1400 mg daily (weight-based) by mouth twice daily followed by PegIntron plus ribavirin plus SCH 900518 600 mg daily plus ritonavir 100 mg daily for 12 weeks.
Depending on HCV-RNA levels after 4 weeks of SCH 900518, patients will receive an additional 8 or 32 weeks of PegIntron/ribavirin.
Total treatment duration will be 24 or 48 weeks.
|
1.5 mcg/kg subcutaneously weekly for up to 24 or 48 weeks
Andere Namen:
ribavirin 600 to 1400 mg daily (weight-based dosing) by mouth twice daily for up to 24 or 48 weeks
Andere Namen:
SCH 900518 100 mg tablets taken as 200 mg PO QD, 100 mg PO BID, 400 mg PO QD, or 600 mg PO QD for 12 weeks.
Ritonavir 100 mg capsules taken as 100 mg PO QD or 100 mg PO BID for 12 weeks.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
The primary efficacy endpoint is the proportion of subjects with undetectable HCV-RNA after 4 weeks of treatment with SCH 900518.
Zeitfenster: After 4 weeks of treatment with SCH 900518
|
After 4 weeks of treatment with SCH 900518
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
Rate of viral decline during the first 4 weeks of dosing with SCH 900518
Zeitfenster: After 4 and 12 weeks of treatment with SCH 900518, at EOT and FW 24
|
After 4 and 12 weeks of treatment with SCH 900518, at EOT and FW 24
|
Proportion of subjects with undetectable HCV-RNA at both 4 and 12 weeks of dosing with SCH 900518
Zeitfenster: After 4 and 12 weeks of treatment with SCH 900518, at EOT and FW 24
|
After 4 and 12 weeks of treatment with SCH 900518, at EOT and FW 24
|
Proportion of subjects with undetectable HCV-RNA at end of treatment (EOT) and follow-up week 24 (FW24)
Zeitfenster: After 4 and 12 weeks of treatment with SCH 900518, at EOT and FW 24
|
After 4 and 12 weeks of treatment with SCH 900518, at EOT and FW 24
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Sponsor
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn
1. November 2008
Primärer Abschluss (Tatsächlich)
1. Juli 2009
Studienabschluss (Tatsächlich)
1. September 2010
Studienanmeldedaten
Zuerst eingereicht
24. November 2008
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
24. November 2008
Zuerst gepostet (Schätzen)
25. November 2008
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
22. Januar 2015
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
21. Januar 2015
Zuletzt verifiziert
1. Januar 2015
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des Verdauungssystems
- RNA-Virusinfektionen
- Viruserkrankungen
- Infektionen
- Durch Blut übertragene Infektionen
- Übertragbare Krankheiten
- Leberkrankheiten
- Flaviviridae-Infektionen
- Hepatitis, viral, menschlich
- Enterovirus-Infektionen
- Picornaviridae-Infektionen
- Hepatitis, chronisch
- Hepatitis
- Hepatitis A
- Hepatitis C
- Hepatitis C, chronisch
- Molekulare Mechanismen der pharmakologischen Wirkung
- Antiinfektiva
- Antivirale Mittel
- Enzym-Inhibitoren
- Anti-HIV-Agenten
- Antiretrovirale Mittel
- Antimetaboliten
- Protease-Inhibitoren
- Cytochrom P-450 CYP3A-Inhibitoren
- Cytochrom-P-450-Enzym-Inhibitoren
- HIV-Protease-Inhibitoren
- Virale Protease-Inhibitoren
- Ribavirin
- Ritonavir
- Peginterferon alfa-2b
Andere Studien-ID-Nummern
- P05104
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Hepatitis C, chronisch
-
Tripep ABInovio PharmaceuticalsUnbekanntChronische Hepatitis-C-VirusinfektionSchweden
-
Trek Therapeutics, PBCAbgeschlossenChronische Hepatitis C | Hepatitis-C-Genotyp 1 | Hepatitis C (HCV) | Hepatitis-C-VirusinfektionVereinigte Staaten, Neuseeland
-
Trek Therapeutics, PBCAbgeschlossenChronische Hepatitis C | Hepatitis C (HCV) | Hepatitis-C-Genotyp 4 | Hepatitis-C-VirusinfektionVereinigte Staaten
-
Hadassah Medical OrganizationXTL BiopharmaceuticalsZurückgezogenChronische Hepatitis-C-VirusinfektionIsrael
-
Hadassah Medical OrganizationUnbekanntChronische Hepatitis-C-VirusinfektionIsrael
-
AbbVieAbgeschlossenHepatitis-C-Virus | Chronisches Hepatitis-C-Virus
-
AbbVieAbgeschlossenChronische Hepatitis C | Hepatitis C (HCV) | Hepatitis-C-Genotyp 1a
-
AbbVie (prior sponsor, Abbott)AbgeschlossenChronische Hepatitis C | Hepatitis-C-Genotyp 1 | Hepatitis C (HCV)Vereinigte Staaten, Australien, Kanada, Frankreich, Deutschland, Neuseeland, Puerto Rico, Spanien, Vereinigtes Königreich
-
ANRS, Emerging Infectious DiseasesUniversité Montpellier; Centre MurazAktiv, nicht rekrutierendChronische Hepatitis c | Hepatitis-C-Virusinfektion, Vergangenheit oder GegenwartBurkina Faso
-
Sohag UniversityRekrutierung
Klinische Studien zur peginterferon alfa 2b
-
Third Affiliated Hospital, Sun Yat-Sen UniversityPeking University; Huazhong University of Science and Technology; First People... und andere MitarbeiterUnbekannt
-
Third Affiliated Hospital, Sun Yat-Sen UniversityPeking University; Huazhong University of Science and Technology; First People... und andere MitarbeiterUnbekanntChronische Hepatitis BChina
-
Third Affiliated Hospital, Sun Yat-Sen UniversityRekrutierungHepatitis B, chronischChina
-
Hoffmann-La RocheAbgeschlossen
-
Hoffmann-La RocheAbgeschlossenHepatitis C, chronischBelgien, Irland, Italien, Vereinigtes Königreich
-
Xiamen Amoytop Biotech Co., Ltd.Peking University First HospitalAbgeschlossen
-
Fang WangRekrutierungChronische HBV-InfektionChina
-
Merck Sharp & Dohme LLCAbgeschlossenHepatitis C, chronisch
-
Guangzhou 8th People's HospitalRekrutierung
-
Xiamen Amoytop Biotech Co., Ltd.Peking University People's HospitalAbgeschlossenChronische Hepatitis CChina